Amneal Pharmaceuticals of New York LLC announced the approval of its abbreviated new drug application (ANDA) for hydrocodone bitartrate and acetaminophen, solidifying its presence in the generic pain management market. This clearance establishes the company as a capable competitor in the high-volume opioid sector, potentially positioning it to capture a significant share of the over-the-counter prescription market.